Opdivo plus Yervoy for patients with hepatocellular carcinoma previously treated with Sorafenib, FDA approved
Opdivo ( Nivolumab ) 1 mg/kg plus Yervoy ( Ipilimumab ) 3 mg/kg ( injections for intravenous use ) was approved by the U.S. Food and Drug Administration ( FDA ) to treat hepatocellular carcinoma ( HCC ) in patients who have been previously treated with Sorafenib.
Approval for this indication has been granted under accelerated approval based on overall response rate and duration of response seen in the Opdivo plus Yervoy cohort of the phase 1/2 CheckMate -040 trial.
Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
In the CheckMate -040 cohort of HCC patients previously treated with Sorafenib, after a minimum follow up of 28 months, 33% ( 16/49; 95% CI: 20-48 ) of patients responded to treatment with Opdivo plus Yervoy; 8% ( 4/49 ) had a complete response ( CR ) and 24% ( 12/49 ) had a partial response ( PR ).
Duration of responses ( DOR ) ranged from 4.6 to 30.5+ months, with 88% lasting at least six months, 56% at least 12 months and 31% at least 24 months.
Overall response rate ( ORR ) and DOR were assessed by BICR ( Blinded Independent Central Review ) using RECIST v1.1.
ORR assessed by BICR using modified RECIST was 35% ( 17/49; 95% CI: 22-50 ), with a CR reported in 12% ( 6/49 ) of patients and a PR reported in 22% ( 11/49 ) of patients.
CheckMate -040 is a phase 1/2 open-label study that included a cohort of patients with HCC who progressed on or were intolerant to Sorafenib and received Nivolumab plus Ipilimumab.
The trial included patients who were PD-L1 expressors and non-expressors.
Key eligibility criteria included histologic confirmation of HCC and Child-Pugh Class A cirrhosis status. Additional eligibility criteria included those who were infected with active HCV or active HBV, or were uninfected.
Patients with active autoimmune disease, brain metastasis, a history of hepatic encephalopathy, clinically significant ascites, infection with HIV, or active co-infection with HBV and HCV or HBV and HDV were excluded.
Patients with known fibrolamellar HCC, sarcomatoid HCC, and mixed cholangiocarcinoma and HCC were also excluded.
A total of 49 patients were treated with Nivolumab 1 mg/kg IV and Ipilimumab 3 mg/kg IV every three weeks for four doses, followed by Nivolumab 240 mg every two weeks until disease progression or unacceptable toxicity.
The major efficacy outcome was ORR, as assessed by BICR using RECIST v1.1 and mRECIST.1 Duration of response was also assessed.
The safety of Opdivo 1 mg/kg and Yervoy 3 mg/kg was evaluated in 49 patients. Serious adverse reactions occurred in 59% of patients receiving Opdivo plus Yervoy.
Treatment was discontinued in 29% of patients and delayed in 65% of patients for an adverse reaction.
Serious adverse reactions reported in greater than or equal to 4% of patients were pyrexia, diarrhea, anemia, increased AST, adrenal insufficiency, ascites, esophageal varices hemorrhage, hyponatremia, increased blood bilirubin, and pneumonitis.
The most common adverse reactions ( reported in greater than or equal to 20% of patients ) were rash ( 53% ), pruritus ( 53% ), musculoskeletal pain ( 41% ), diarrhea ( 39% ), cough ( 37% ), decreased appetite ( 35% ), fatigue ( 27% ), pyrexia ( 27% ), abdominal pain ( 22% ), headache ( 22% ), nausea ( 20% ), dizziness ( 20% ), hypothyroidism ( 20% ), and weight decreased ( 20% ). ( Xagena )
Source: BMS, 2020
The nucleoside-modified messenger RNA in COVID-19 mRNA vaccine BNT162b2 is formulated in lipid nanoparticles, which enable delivery of the RNA...
Initial preliminary findings from the Papa Giovanni XXIII Hospital sponsored SISCO ( Siltuximab In Serious COVID-19 ) Study, based on...
Adults and children with all genotypes of hepatitis C and compensated cirrhosis: Mavyret shortens duration of treatment to eight weeks, approved by FDA
The FDA ( U.S. Food and Drug Administration ) has expanded the approval of Mavyret ( Glecaprevir and Pibrentasvir )...
Results from the largest study of hepatitis B and C and HIV infection prevalence in cancer patients show an alarmingly...
FDA has approved Dovato, the first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment
The FDA ( U.S. Food and Drug Administration ) has approved Dovato ( Dolutegravir and Lamivudine ), as a complete...
Dovato, based on Dolutegravir and Lamivudine, a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection, approved in European Union
The European Commission has granted Marketing Authorisation for Dovato ( Dolutegravir / Lamivudine ) for the treatment of HIV-1 infection...
The results of a study has shown that patients living with HIV and one of a variety of potentially deadly...
HIV-1 control with a 2-drug regimen of Dolutegravir plus Lamivudine in virally suppressed patients switching from a TAF-containing 3-drug regimen
Week 48 results from phase III TANGO study were announced. The TANGO study was conducted to assess whether adults living...
Biktarvy: Bictegravir, Emtricitabine, Tenofovir Alafenamide approved by FDA for treatment of HIV-1 infection
The FDA ( U.S. Food and Drug Administration ) has approved Biktarvy ( Bictegravir 50mg / Emtricitabine 200mg / Tenofovir...